Back to results

TerminatedPhase 3

Efficacy and Safety of Memantine in Moderate to Severe Alzheimer's Disease

NCT00857649

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

CA019

Edmonton, Alberta, Canada

+22 additional locations

View on ClinicalTrials.gov

Save this trial

Quick facts

Start date: 2003-12
Enrollment: 369 participants
Sponsor: H. Lundbeck A/S
Purpose: treatment

Locations (23)

CA019Edmonton, Alberta, Canada
CA033Kelowna, British Columbia, Canada
CA034Winnipeg, Manitoba, Canada
CA022Saint John, New Brunswick, Canada
CA046Kentville, Nova Scotia, Canada
CA045Pictou, Nova Scotia, Canada
CA032Burlington, Ontario, Canada
CA029Orangeville, Ontario, Canada
CA004Ottawa, Ontario, Canada
CA038Peterborough, Ontario, Canada
CA009Toronto, Ontario, Canada
CA037Windsor, Ontario, Canada
CA005Beauport, Quebec, Canada
CA023Greenfield Park, Quebec, Canada
CA013Montreal, Quebec, Canada
CA031Sherbrooke, Quebec, Canada
CA012Sherbrooke, Quebec, Canada
CA030Vanier, Quebec, Canada
CA017Verdun, Quebec, Canada
CA015Regina, Saskatchewan, Canada
CA040Saskatoon, Saskatchewan, Canada
CA043Kelowna, Canada
CA042Penticton, Canada

Efficacy and Safety of Memantine in Moderate to Severe Alzheimer's Disease — TrialFind